PainReform cut to Hold at Maxim amid ‘changed' market dynamics [Yahoo! Finance]
PainReform Ltd. - Ordinary Shares (PRFX)
Company Research
Source: Yahoo! Finance
The company is developing PRF-110 to treat post-operative pain and compete in the market with Exparel and Zynrelef, but market dynamics have recently changed, with a generic for Exparel – the market leader – having been approved in July 2024 and impacting the market opportunity for PainReform and its operational ramifications, the analyst tells investors in a research note. Maxim adds that PainReform is on pace to complete its Phase 3 bunionectomy study in Q4, noting however that the company still needs to complete a soft tissue study and potentially a third study for the safety database, and the firm believes that additional capital will likely be required to complete these studies. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now See Insiders' Hot Stocks on TipRanks Read More on PRFX: PainReform downgraded to Hold from Buy at Maxim PainReform Announces Significant Share Offering PainReform Calls Shareholder Me
Show less
Read more
Impact Snapshot
Event Time:
PRFX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRFX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRFX alerts
High impacting PainReform Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRFX
News
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialGlobeNewswire
- PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement [Yahoo! Finance]Yahoo! Finance
- PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity RequirementGlobeNewswire
- PainReform Ltd. (NASDAQ: PRFX) had its "hold" rating re-affirmed by analysts at Maxim Group.MarketBeat
PRFX
Sec Filings
- 12/13/24 - Form EFFECT
- 12/12/24 - Form 424B3
- 12/6/24 - Form F-3
- PRFX's page on the SEC website